SCHEMBL286612

SCHEMBL286612

O=C1OCc2c1ccc(Br)c2I

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNJ1 P48048 9/20 0.44
MAOA P21397 2/20 0.38
MAOB P27338 2/20 0.38
KCNH2 Q12809 7/20 0.38
MAPT P10636 2/20 0.37
LMNA P02545 2/20 0.37
GAA P10253 1/20 0.37
ACHE P22303 1/20 0.35
SSTR1 P30872 1/20 0.35
SLC6A4 P31645 1/20 0.35
ALOX5 P09917 1/20 0.34
ALDH1A1 P00352 2/20 0.33
RECQL P46063 1/20 0.33
PRF1 P14222 1/20 0.33
KDM4E B2RXH2 1/20 0.33
TYMS P04818 1/20 0.33
CYP1A2 P05177 1/20 0.33
HPGD P15428 1/20 0.33
CYP2C19 P33261 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2731592 0.82 HSD11B1 (0.35) KCNJ1MAOAMAOBMAPTALDH1A1
SCHEMBL855079 0.81 KCNJ1 (0.46) KCNJ1MAOAMAOBKCNH2MAPT
SCHEMBL32673165 0.81 KCNJ1 (0.46) KCNJ1MAOAMAOBKCNH2MAPT
SCHEMBL29915113 0.78 KCNJ1 (0.44) KCNJ1MAOAMAOBKCNH2MAPT
SCHEMBL286899 0.78 KCNJ1 (0.60) KCNJ1MAOAMAOBKCNH2LMNA
SCHEMBL286864 0.78 KCNJ1 (0.44) KCNJ1MAOAMAOBKCNH2MAPT
SCHEMBL2733555 0.78 KCNJ1 (0.44) KCNJ1MAOAMAOBKCNH2MAPT
SCHEMBL30445186 0.78 KCNJ1 (0.60) KCNJ1MAOAMAOBKCNH2LMNA
SCHEMBL20231338 0.78 KCNJ1 (0.44) KCNJ1MAOAMAOBKCNH2MAPT
SCHEMBL26738187 0.78 KCNJ1 (0.44) KCNJ1MAOAMAOBKCNH2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028354-A1 TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS REGENT OF THE UNIV OF MICHIGAN (US) 2026-01-29 US disclosed
US-20260007681-A1 INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS UNIV MICHIGAN (US) 2026-01-08 US disclosed
EP-4656642-A1 ESTROGEN RECEPTOR PROTEOLYSIS TARGETING CHIMERA COMPOUND AND USE THEREOF GAN & LEE PHARM CO., LTD (CN) 2025-12-03 EP disclosed
US-20250360219-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS INC (US) 2025-11-27 US disclosed
US-20250195484-A1 CEREBLON LIGANDS AND USES THEREOF UNIV MICHIGAN (US) 2025-06-19 US disclosed
EP-4554948-A1 TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS Regents of the University of Michigan (US) 2025-05-21 EP disclosed
US-20250129088-A1 CEREBLON E3 UBIQUITIN LIGASE INHIBITOR GAN & LEE PHARMACEUTICALS CO., LTD. (CN) 2025-04-24 US disclosed
US-12239711-B2 Cereblon ligands and bifunctional compounds comprising the same ARVINAS OPERATIONS, INC. (US) 2025-03-04 US disclosed
WO-2025026283-A1 COMPOUND FOR SELECTIVELY DEGRADING SMARCA2/4 AND USE THEREOF 甘李药业股份有限公司 2025-02-06 WO disclosed
EP-4471033-A1 CEREBLON E3 UBIQUITIN LIGASE INHIBITOR Gan & Lee Pharmaceuticals Co., Ltd. (CN) 2024-12-04 EP disclosed
US-20140031349-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2014-01-30 US disclosed
WO-2014018764-A1 SPIRO - FUSED PIPERIDINE DERIVATIVES FOR USE AS INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2014-01-30 WO disclosed
EP-2632464-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL Merck Sharp & Dohme Corp. (US) 2013-09-04 EP disclosed
US-20130217680-A1 Inhibitors of the Renal Outer Medullary Potassium Channel MERCK SHARP & DOHME LLC 2013-08-22 US disclosed
WO-2013066714-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2013-05-10 WO disclosed
WO-2013028474-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2013-02-28 WO disclosed
WO-2012058134-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2012-05-03 WO disclosed
EP-2427444-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL Merck Sharp & Dohme Corp. (US) 2012-03-14 EP disclosed
WO-2010129379-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2010-11-11 WO disclosed
US-20100286123-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME LLC 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129088-A1 CEREBLON E3 UBIQUITIN LIGASE INHIBITOR CRBN, UBE3A, UBE3C KCNJ1 4724/4885MAOA 3275/4885MAOB 2847/4885
US-20250360219-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME CRBN, CBL, MDM2 KCNJ1 4871/4885MAOA 2494/4885MAOB 2964/4885
US-12239711-B2 Cereblon ligands and bifunctional compounds comprising the same CRBN, CBL, MDM2 KCNJ1 4871/4885MAOA 2494/4885MAOB 2964/4885
US-20250195484-A1 CEREBLON LIGANDS AND USES THEREOF CRBN, CDR2, CHLSN KCNJ1 4883/4885MAOA 1746/4885MAOB 1631/4885
US-20260028354-A1 TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS ESRRA, ESR2, ESRRB KCNJ1 4457/4885MAOA 715/4885MAOB 384/4885
US-20130217680-A1 Inhibitors of the Renal Outer Medullary Potassium Channel KCNJ11, KCNJ1, KCNJ2 KCNJ1 2/4885MAOA 2569/4885MAOB 2151/4885
US-20260007681-A1 INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS ESRRA, ESR2, AR KCNJ1 4357/4885MAOA 237/4885MAOB 195/4885
US-20100286123-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL KCNJ11, KCNJ1, KCNJ2 KCNJ1 2/4885MAOA 2724/4885MAOB 2314/4885
US-20140031349-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL KCNJ11, KCNJ1, KCNJ2 KCNJ1 2/4885MAOA 3445/4885MAOB 2651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.